2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD47
  5. CD47 Inhibitor

CD47 Inhibitor

CD47 Inhibitors (25):

Cat. No. Product Name Effect Purity
  • HY-16438
    RRx-001
    		Inhibitor 99.16%
    RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.
  • HY-P99029
    Magrolimab
    		Inhibitor
    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer.
  • HY-P99172
    CC-90002
    		Inhibitor
    CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors.
  • HY-143224B
    NCGC00138783 TFA
    		Inhibitor 99.71%
    NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis.
  • HY-P99175
    KWAR 23
    		Inhibitor 99.80%
    KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
  • HY-P990858
    Anti-CD47 Antibody (B6.H12)
    		Inhibitor
    Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P99950
    Evorpacept
    		Inhibitor
    Evorpacept (ALX148) is an anti-CD47 monoclonal antibody.
  • HY-P990723
    Timdarpacept
    		Inhibitor
    Timdarpacept is an anti-CD47 monoclonal antibody.
  • HY-P99026
    Lemzoparlimab
    		Inhibitor
    Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.
  • HY-P99777
    Ontorpacept
    		Inhibitor
    Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
  • HY-P990033
    Anzurstobart
    		Inhibitor 98.53%
    Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.
  • HY-P99706
    Ligufalimab
    		Inhibitor 98.81%
    Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.
  • HY-P0144
    Thrombospondin-1 (1016-1023) (human, bovine, mouse)
    		Inhibitor 99.08%
    Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide.
  • HY-115983
    DMUP
    		Inhibitor ≥98.0%
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity.
  • HY-P99533
    Urabrelimab
    		Inhibitor 98.49%
    Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.
  • HY-151132
    Glutaminyl cyclases-IN-1
    		Inhibitor 98.21%
    Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC50 values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages.
  • HY-P990132
    Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)
    		Inhibitor
    Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.
  • HY-143224
    NCGC00138783
    		Inhibitor
    NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis.
  • HY-P990131
    Anti-Mouse CD47/IAP Antibody (MIAP301)
    		Inhibitor
    Anti-Mouse CD47/IAP Antibody (MIAP301) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD47/IAP.
  • HY-P10388
    TAX2 peptide
    		Inhibitor
    TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2/KDR/Flk-1 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment.